According to p53, p21 in tumor cell response to cytotoxic medicines, as well as the potential to increase the therapeutic index of such agents by altering p21 status through p53-dependent pathways, which was detected in HCT-116 [46], but not in HT29, which has a deficiency in p53 gene expression [47]. The gene discussed is TP53; the disease is neoplasm.